Poland· PL-100077413
Gasprid
A cisapride product containing cisapridum, registered in Poland by Teva Pharmaceuticals Polska Sp. z o.o.. The same ATC class is registered in 4 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Cisapride is registered in 4 of 19 countries.
Countries holding a registration under ATC A03FA02 (cisapride), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Cisapride · ATC A03FA02
4 / 19 countries
- Finlandprice
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Cisapridum
- Manufacturer
- Teva Pharmaceuticals Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- A03FA02
- ATC class
- Cisapride
- Defined daily dose
- 30 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990732418
- gtin05909990732425
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
367 interactions on record for cisapride.
Graded by severity as the source publishes them — 276 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cisapride · interactions on record
367 records
- 276 severe
- 85 moderate
- 6 minor
Most severe, free to view
- CimetidineA02BA01severe
- PapaverineA03AD01severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cisapride in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7240f32d-ca4b-4a4d-9142-dcbacecd9171 GET /v1/drugs/7240f32d-ca4b-4a4d-9142-dcbacecd9171?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "10 mg",
"packaging": "Rp ¦ Skasowane ¦ 11658\n30 tabl.\n05909990732418 ¦ Rp ¦ 16700\n30 tabl.\n05909990732425 ¦ Rp ¦ Skasowane ¦ 16728\n30 tabl. w pojemniku",
"substance": "Cisapridum 10 mg",
"common_name": "Cisapridum",
"pl_product_id": "100077413",
"pozwolenie_nr": "07324",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about cisapride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.